A Prediction Model for Cure of Peritoneal Dialysis-Associated Peritonitis: A Multicenter Study

Lingfei Meng
The Second Hospital of Jilin University

Liming Yang
The First Hospital of Jilin University-the Eastern Division

Xueyan Zhu
Jilin Central Hospital

Xiaoxuan Zhang
Jilin FAW General Hospital

Xinyang Li
The Second Hospital of Jilin University

Siyu Cheng
The Second Hospital of Jilin University

Shizheng Guo
The Second Hospital of Jilin University

Xiaohua Zhiang
The Second Hospital of Jilin University

Hongbin Zou
The Second Hospital of Jilin University

Ping Luo
The Second Hospital of Jilin University

Wenpeng Cui (wenpengcui@163.com)
The Second Hospital of Jilin University

Research Article

Keywords: Peritoneal dialysis, Peritoneal Dialysis-Associated Peritonitis, Clinical decision rules, Nomogram

Posted Date: December 16th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1122344/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Aim

Peritoneal dialysis (PD)-associated peritonitis (PDAP) is a severe complication of PD. And it is an important issue about whether it can be cured. At present, there is no available prediction model for peritonitis cure. Therefore, the present work aimed to develop and validate a risk prediction model for peritonitis cure in PDAP patients.

Methods

PD patients who developed PDAP from four dialysis centers in Northeast China were followed up. According to the region of PD, data were divided into training and validation datasets. First of all, a nomogram for peritonitis cure was established based on the training dataset. Later, performance of the nomogram model was assessed by discrimination (C-statistic), calibration and decision curves.

Results

In total, 1063 episodes of peritonitis were included in the final analysis, including 806 in the training dataset and 257 in the validation dataset. During the follow-up period, 621 and 199 cases in the training and validation datasets, respectively, reported peritonitis cure. Predictors incorporated in the final nomogram model included PD duration, serum albumin, antibiotics prior to admission, and type of causative organisms. The C-statistic values were 0.76 (95% CI: 0.72–0.80) in the training dataset and 0.77 (95% CI: 0.70–0.84) in the validation dataset. The nomogram exhibited favorable performance in terms of calibration in both the training and validation datasets.

Conclusion

This study develops a practical and convenient nomogram for the prediction of peritonitis cure in PDAP patients, which assists in the clinical decision-making.

Introduction

Aim

End-stage renal disease (ESRD) is a condition characterized by a high mortality rate and reduced quality of life, and for patients receiving dialysis, they experience tremendous burdens. Peritoneal dialysis (PD) is a home-based and cost-effective dialysis modality for ESRD patients, which can be customized depending on the value, expectation, and lifestyle of patients. PD has been increasingly utilized in many countries over the past decade, and China is becoming a country with the largest number of PD patients in the world. In light of the rapid spread of coronavirus disease 2019 (COVID-19) throughout the world, PD offers a great advantage over hemodialysis (HD) as an efficient renal replacement therapy with a low risk of coronavirus infection.
Peritoneal dialysis-associated peritonitis (PDAP) is a severe complication of PD. The incidence rate and outcome of peritonitis vary greatly across different countries. Despite the application of appropriate antibiotic therapy, PDAP still affects the mortality and technological survival rates of patients, and contributes to the added hospitalization events and treatment costs. On the other hand, severe peritonitis episodes may progress to encapsulating peritoneal sclerosis, which precludes successful PD. It is a crucial clinical issue for clinicians to get a better outcome of this patient population. If individual peritonitis cure can be predicted based on the comprehensive assessment of the patient's condition, a precise therapy and care strategy can be implemented to minimize patient sufferings and save medical resources.

Several prognostic factors for PDAP cure have been reported in studies, including modifiable risk factors and nonmodifiable risk factors. However, to our knowledge, there is few available prediction model for the outcome of peritonitis at present. Therefore, this study aimed to establish and validate a prediction nomogram model to guide clinical decision-making and improve the quality of PDAP treatment.

**Materials And Methods**

**Study participants**

All PD patients who developed PDAP during the study period from January 1st, 2013 to December 31st, 2019 were included and followed up in this study. Altogether 1145 PDAP episodes were collected from four dialysis centers in Northeast China (Second Hospital of Jilin University, First Hospital of Jilin University, Jilin FAW General Hospital, and Jilin Central Hospital). The diagnosis of PDAP was made based on the presence of any two of the following features: (1) clinical features consistent with peritonitis, i.e., abdominal pain and/or cloudy dialysis effluent; (2) white cell count (WBC) in dialysis effluent > 100/μL after a dwell time of at least 2 h, with > 50% polymorphonuclear leucocytes; and (3) positive culture of dialysis effluent. Meanwhile, the patient exclusion criteria were as follows, (1) those whose medical records were incomplete, (2) those younger than 18 years old, (3) those whose dialysis effluent was not cultured, (4) those treated with immunosuppressant medications, and (5) those with chronic liver disease at the time of PD diagnosis. According to the different regions of PDAP patients, data were divided into training (First Hospital of Jilin University, Jilin Central Hospital) and validation (Jilin FAW General Hospital, Second Hospital of Jilin University) datasets. In line with the guidelines set forth by the International Society for Peritoneal Dialysis, PDAP was treated with standard antibiotics covering both gram-positive and gram-negative pathogens. Once the culture results and sensitivities were known, antibiotic therapy was adjusted to narrow-spectrum agents. Treatment with effective antibiotics lasted for 2-3 weeks according to the type of organism. PD catheters were removed in accordance with the ISPD peritonitis recommendation. Informed consent was waived due to the retrospective and non-interventional design of this study by the Ethics Committee of Second Hospital of Jilin University (No. 2020026). Members of the Ethics Committee of Second Hospital of Jilin University are as follows: Wei Yang; Xiujuan Fu; Yajuan Zheng; Jincheng Wang; Tiejun Wang; Bin Liu; Pinghui Sun;
Tianmin Xu; Zhonghai Yan; Xuan Zhang; Xuewen Zhang; Yunfeng Zhang; Junling Yang; Yanling Yin; Huiling Ji; Zhenghong Yan. All procedures in this study were performed in line with the Helsinki declaration.

**Data collection**

Clinical information, including prognostic factors associated with peritonitis cure in PD, was retrieved from the medical records of patients\textsuperscript{11-13}. For each episode of peritonitis, we recorded the patient age at the time of PDAP, gender, number of PDAP episodes, PD duration, antibiotics used prior to admission, presence of protopathy and comorbidities [such as hypertension, diabetes mellitus (DM) or cardiovascular disease (CVD)]. Additionally, we also recorded results of various laboratory tests, including WBC count, serum albumin, hemoglobin, blood urea nitrogen (BUN), serum creatinine, blood ions (sodium, potassium, calcium, phosphorus), PD cell count on admission, presence of causative organisms, and exit-site infection. Further, the causative organisms in effluent samples were subcategorized into culture-negative organisms, gram-positive (Staphylococcus aureus, Coagulase-negative Staphylococcus, Corynebacterium, Enterococcus, others), gram-negative (Pseudomonas aeruginosa, Escherichia coli, Klebsiella Pneumoniae, Enterobacter species, others), polymicrobial, Mycobacterium tuberculosis or fungi. Polymicrobial peritonitis was defined as the presence of two or more cultured pathogens in the PD solution. All biochemical measurements were completed using the standard laboratory techniques.

**Outcome**

The primary outcome of interest was peritonitis cure, which was defined as the absence of a subsequent peritonitis event (relapse or recurrence), PD catheter removal, or transfer to HD (deemed permanent transfer to HD, or temporary transfer with failure to return to PD within the modality switch date 84 days), or death within 50 days after the onset of a peritonitis episode\textsuperscript{14}.

**Statistical analysis**

Logistic regression was utilized to determine the potential outcome predictors in the training dataset. Risk factors associated with peritonitis cure were identified through univariate analysis, then, the significant risk factors were further incorporated into the multivariate logistic regression model. Thereafter, a nomogram was constructed based on the multivariate logistic regression model to calibrate the probability estimates of peritonitis cure individually. In the nomogram model, categorical covariates were considered as dummy variables. All variables incorporated in logistic regression were predictors with <10% of missing values. Continuous variables were interpolated by mean or median according to the type of distribution, whereas categorical variables were interpolated by mode.

Internal validation was accomplished in the entire training dataset. Moreover, the C-statistic was calculated to assess the model discrimination using Stata, and the calibration curve was subsequently plotted.
External validation was performed in the validation dataset based on the prediction model. The predicted value was obtained by employing the prediction function of Stata. Thereafter, the C-statistic was calculated to assess the model discrimination, and the calibration curve was plotted. Moreover, decision curves were also plotted to evaluate the clinical usefulness of the nomogram.

Statistical analysis was carried out using SPSS (version 22.0, IBM, New York, United States) and Stata (version 15.0; StataCorp LP) software. A $P$-value less than 0.05 was considered as statistically significant.

Results

Characteristics of study participants

During the study period, 1145 episodes of peritonitis from all the four centers met the criteria for PDAP. Among these candidate participants, 60 were excluded due to missing data, immunosuppressant medications, or liver disease at the initiation of PD. Additionally, 10 were further eliminated for being younger than 18 years of age, and 12 for no culture of dialysis effluent (Figure 1). Therefore, 1063 episodes of PDAP were finally included for analysis. Among them, 820 episodes were cured, yielding the overall cure rate of 77.1%. According to the region of PDAP, the episodes were divided into training ($n = 806$) and validation ($n = 257$) datasets. During the follow-up period, 621 and 199 cases of peritonitis cure were observed in the training and validation datasets, respectively. Patient demographics, clinical manifestations, and laboratory parameters in the training dataset recorded at baseline are shown in Table 1.

Model establishment

In this study, the prediction model was established based on the training dataset. Upon univariate analysis, four variables (including PD duration, serum albumin, antibiotics prior to admission, and type of causative organisms) were significantly associated with peritonitis cure. Therefore, these four predictors were incorporated into the final prediction model for multivariable analysis (Table 2). A nomogram for the practical application of this model is displayed in Figure 2. Its usage was illustrated with a hypothetical patient with PD duration of 1 year, no antibiotics prior to admission, a serum albumin of 40 g/L, and Escherichia coli infection (Figure 2, vertical lines). The points for PD duration, no antibiotics prior to admission, serum albumin and bacterial infection for this patient were 2.5, 1.5, 3 and 7, respectively, resulting in the total points of 14, which represented approximately 0.84 of cure probability. It assisted in the identification of patients with a high or low probability of cure. If it intended to be cure, continuous maintenance of antibiotic therapy should be given. If it intended not to be cure, early catheter removal and device insertion for temporary HD might be advised.

Model validation

*Internal validation of the prediction model*
In the training dataset, the C-statistic for the prediction of peritonitis cure by the constructed nomogram was 0.76 (95% CI: 0.72–0.80) (Figure 3a), indicating reasonable model discrimination. Besides, the calibration curve demonstrated that the probability of peritonitis cure predicted by the nomogram was relatively well matched with the actual measurement (Figure 3b).

**External validation of the prediction model**

In the validation dataset, the C-statistic for the prediction of peritonitis cure by the constructed nomogram was 0.77 (95% CI: 0.70–0.84) (corresponding ROC curve is displayed in Figure 4a). In addition, the calibration curve exhibited good agreement between the nomogram-predicted value and the actual measurement (Figure 4b). A decision curve was also plotted to evaluate the clinical usefulness of the nomogram (Figure 5). Based on the above results, our nomogram accurately predicted patients with or without cure.

**Discussion**

A novel prediction model for peritonitis cure among PDAP patients was established and validated in this multicenter study. PD duration, serum albumin, antibiotics prior to admission, and type of causative organisms were included in the prediction model. Based on our results, the as-constructed model showed good performances in calibration and discrimination, with the C-statistic of over 0.75. Using the nomogram, it is possible to stratify individual peritonitis episodes and make reasonable treatment decisions. To our knowledge, this is the first prediction nomogram for predicting PDAP cure in patients initializing PD developed in a multicenter study.

There are few reports concerning the prediction model of peritonitis cure in PDAP population. Surapon Nochaiwong et al. developed a prediction score for the treatment failure among PD patients, which incorporated DM, systolic blood pressure (SBP), dialysate leukocyte count on day 3–4, and dialysate leukocyte count on day 5. Nevertheless, their model did not incorporate pathogenic bacteria, and no external validation was conducted. Different from this study, their outcome was treatment failure containing catheter removal, transfer to HD, or peritonitis-associated mortality. As a matter of fact, their risk factors for the outcome were inconsistent.

In our study, the prediction nomogram model was more intuitive and applicable to clinical practice. The treatment decision should be made by taking into comprehensive consideration of a PDAP patient. According to our results, a shorter PD duration was related to the possibility of peritonitis cure, which was supported by several reports. For instance, a study found that PD duration less than 2.4 years was associated with a higher resolution rate than that longer than 2.4 years. Another study indicated that a longer PD duration at the onset of peritonitis was related to a longer duration from PD effluent abnormalities to treatment with appropriate antibiotics, which further led to adverse outcomes. Similar finding was also obtained from other study, which was that patients receiving long-term dialysis were prone to gram-negative bacterial infection and worse
treatment outcomes compared with those undergoing short-term dialysis\textsuperscript{18}. There are inconsistent results regarding the impact of PD duration on the outcome of PDAP in literature. For instance, Yang \textit{et al.} did not find the relationship between PD duration and catheter loss\textsuperscript{19}. The differences may be ascribed to the different definitions of study outcome. Our data confirmed that the increased PD duration reduced the probability of peritonitis cure in all the episodes of peritonitis. We infer that continuous exposure to glucose and glucose degradation products may lead to tissue toxicity in the peritoneum, resulting in peritoneal dysfunction\textsuperscript{20}. This may further make it difficult to eliminate inflammation.

Another novel predictive factor for cure identified in this study was no antibiotics prior to admission. As far as we know, the relationship between antibiotics prior to admission and PDAP outcome remains unclear so far. On the one hand, the application of antibiotics at home may be related to serious patient condition, which results in the low possibility of cure. On the other hand, some patients applying antibiotics by themselves live far away from the PD center, and the remote distance from the hospital is also one of the risk factors for peritonitis and technique failure\textsuperscript{21}. Moreover, in our study, the application of antibiotics was not standardized at home by PDAP patients, which delayed the optimal timing of standard treatment\textsuperscript{17} and added to the difficulty in cure.

It was observed in this dataset that a higher level of serum albumin predicted a higher probability of peritonitis cure. In contrast to our study, one article considered that serum albumin level did not affect the non-resolution of peritonitis\textsuperscript{22}. Another study reported that serum albumin was not the risk factor for the poor outcomes of PDAP patients\textsuperscript{23}. Such differences may be attributed to their relatively small sample sizes that are insufficient to find the association between serum albumin and the outcome of PDAP. Hypoalbuminemia is identified as a risk factor for peritonitis in PD patients\textsuperscript{24-26}. As reported in one study, hypoalbuminemia, a marker of malnutrition and inflammation, also predicted the all-cause, cardiovascular, and infection-related mortality in patients receiving PD\textsuperscript{27}. Moreover, a higher daily protein intake in PD patients indicates a higher serum albumin level and good nutrition status, which prevent patient death or peritonitis\textsuperscript{28}. It is not hard to infer that a higher serum albumin level is related to the cure of PDAP. Theoretically, a higher serum albumin level has a good remedial effect when antibiotics are bound onto the serum albumin and the drug metabolism is reduced. We found that a high serum albumin level was good for the cure of PDAP, and it was assumed that treatment strategies to improve albumin levels should be advocated to improve the treatment outcome of peritonitis.

Noteworthily, the causative organism was included in the prediction model. As a matter of fact, the causative organism is an important factor for the outcome of PDAP. However, the specific effects on outcome between some bacteria are unclear. Our constructed nomogram allowed to intuitively observe the concrete effects of different bacteria on cure. In our study, Enterococcus showed the highest score to cure, followed by other \textit{G}-positive Corynebacteria. Then, Cocoagulase-negative \textit{Staphylococcus} and culture-negative organisms had the same score. In Htay's study\textsuperscript{29}, causative organisms were related to the outcome of
PDAP; The authors divided pathogenic bacteria into Gram-positive, Gram-negative, Culture-negative, Polymicrobial organisms and others, and found that Culture-negative bacteria had a higher cure rate than Gram-positive ones. Another study indicated that less virulent causative organisms (coagulase-negative staphylococci, and culture-negative streptococci) were associated with a higher probability of cure\textsuperscript{10}. The prognosis of gram-negative bacterial peritonitis was worse than that of Gram-positive bacterial peritonitis in our study, consistent with Fung's study\textsuperscript{30}. In the present work, bacterial classification was more detailed according to the ISPD peritonitis guidelines, which overcame the problem of different prognosis of different Gram-positive or Gram-negative bacteria. Pathogenic bacteria contained in our model were specific and suitable for clinical applications.

To the best of our knowledge, this is the first nomogram that provides clinicians with a predictable assessment tool for the cure of peritonitis among PDAP patients. Our research has a few strengths. First, our findings serve as the useful reference for the management of PDAP episodes by physicians, which rely on comprehensive assessment rather than a single factor. The external utility of the model is good and can be generalized. Timely ceasing PD can reduce the length of hospital stay, medical costs, and occurrence of serious complications in patients with a low probability of PDAP cure. Furthermore, the nomogram is practical because all the variables included are the easily and routinely collected clinical factors, which offers an intuitive tool for individualized prediction using a small number of risk factors.

Nonetheless, several limitations should also be noted in this study. First, given the retrospective nature of this study, there might be potential selection bias. Second, we did not take into account new biomarkers such as IL-6, COX-2, RNase 3 and RNase \textsuperscript{31, 32}. Future studies should develop or update the prediction model to include new biomarkers. Besides, a larger population size and prospective investigations are also warranted.

**Conclusion**

In conclusion, this study develops a practical and convenient nomogram with good accuracy in estimating the probability of peritonitis cure among PDAP patients, which assists in the clinical decision-making.

**Declarations**

**Acknowledgement**

The authors thank the staff from all the four PD centers for their efforts in collecting patient data.

**Funding**

The current study was supported by the Jilin Province Health and Technology Innovation Development Program Funded Project (No.2017Q024 and No. 2018FP031).
Competing interests
The authors declare no competing interests.

Authors' contributions
Lingfei Meng explored the data and wrote this manuscript. Xinyang Li, Siyu Cheng, Shizheng Guo, Xiaohua Zhuang and Hongbin Zou collected the data. Liming Yang, Xueyan Zhu and Xiaoxuan Zhang provided the data. Ping Luo organized the study. Wenpeng Cui designed this study and reviewed this manuscript.

Consent to participate
Informed consent was exempt, due to the retrospective and non-interventional design of this study.

Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.

References
1. Marrufo, G., Colligan, E., Negrusa, B., Ullman, D., Messana, J., Shah, A., Duvall, T., and Hirth, R. (2020) Association of the Comprehensive End-Stage Renal Disease Care Model With Medicare Payments and Quality of Care for Beneficiaries With End-Stage Renal Disease, *JAMA internal medicine* 180, 852-860.

2. (!!! INVALID CITATION !!!).

3. Li, P. K., Chow, K. M., Van de Luijtgaarden, M. W., Johnson, D. W., Jager, K. J., Mehrotra, R., Naicker, S., Pecoits-Filho, R., Yu, X. Q., and Lameire, N. (2017) Changes in the worldwide epidemiology of peritoneal dialysis, *Nature reviews. Nephrology* 13, 90-103.

4. Yu, X., and Yang, X. (2015) Peritoneal dialysis in China: meeting the challenge of chronic kidney failure, *American journal of kidney diseases : the official journal of the National Kidney Foundation* 65, 147-151.

5. Quintaliani, G., Reboldi, G., Di Napoli, A., Nordio, M., Limido, A., Aucella, F., Messa, P., and Brunori, G. (2020) Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology, *Journal of nephrology* 33, 725-736.

6. Mehrotra, R., Devuyst, O., Davies, S. J., and Johnson, D. W. (2016) The Current State of Peritoneal Dialysis, *J. Am. Soc. Nephrol.* 27, 3238-3252.

7. Li, P. K., Szeto, C. C., Piraino, B., de Arteaga, J., Fan, S., Figueiredo, A. E., Fish, D. N., Goffin, E., Kim, Y. L., Salzer, W., Struijk, D. G., Teitelbaum, I., and Johnson, D. W. (2016) ISPD Peritonitis
Recommendations: 2016 Update on Prevention and Treatment, *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis* 36, 481-508.

8. Howard, K., Hayes, A., Cho, Y., Cass, A., Clarke, M., and Johnson, D. (2015) Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial, *American journal of kidney diseases : the official journal of the National Kidney Foundation* 65, 773-779.

9. Johnson, D., Cho, Y., Livingston, B., Hawley, C., MacDonald, S., Brown, F., Rosman, J., Bannister, K., and Wiggins, K. (2010) Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes, *Kidney international* 77, 904-912.

10. Htay, H., Cho, Y., Pascoe, E. M., Darssan, D., Nadeau-Fredette, A. C., Hawley, C., Clayton, P. A., Borch, M., Badve, S. V., Sud, K., Boudville, N., McDonald, S. P., and Johnson, D. W. (2018) Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry, *American journal of kidney diseases : the official journal of the National Kidney Foundation* 71, 814-821.

11. Yang, C.-Y., Chen, T.-W., Lin, Y.-P., Lin, C.-C., Ng, Y.-Y., Yang, W.-C., and Chen, J.-Y. (2020) Determinants of Catheter Loss following Continuous Ambulatory Peritoneal Dialysis Peritonitis, *Perit. Dial. Int.* 28, 361-370.

12. Krishnan, M., Thodis, E., Ikonomopouloos, D., Vidgen, E., Chu, M., Bargman, J. M., Vas, S. I., and Oreopoulos, D. G. (2020) Predictors of Outcome following Bacterial Peritonitis in Peritoneal Dialysis, *Perit. Dial. Int.* 22, 573-581.

13. Chow, K. M., Szeto, C. C., Cheung, K. K.-T., Leung, C. B., Wong, S. S.-H., Law, M. C., Ho, Y. W., and Li, P. K.-T. (2006) Predictive Value of Dialysate Cell Counts in Peritonitis Complicating Peritoneal Dialysis, *Clin. J. Am. Soc. Nephrol.* 1, 768-773.

14. Al Sahlawi, M., Zhao, J., McCullough, K., Fuller, D., Boudville, N., Ito, Y., Kanjanabuch, T., Nessim, S., Piraino, B., Pisoni, R., Teitelbaum, I., Woodrow, G., Kawanishi, H., Johnson, D., and Perl, J. (2021) Variation in Peritoneal Dialysis-Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS), *American journal of kidney diseases : the official journal of the National Kidney Foundation*.

15. Nochaiwong, S., Ruengorn, C., Koyratkoson, K., Thavorn, K., Awiphan, R., Chaisai, C., Phatthanasobhon, S., Noppakun, K., Suteeky, Y., Panyathong, S., Dandecha, P., Chongruksut, W., and Nanta, S. (2018) A Clinical Risk Prediction Tool for Peritonitis-Associated Treatment Failure in Peritoneal Dialysis Patients, *Sci. Rep.* 8.

16. Krishnan, M., Thodis, E., Ikonomopouloos, D., Vidgen, E., Chu, M., Bargman, J., Vas, S., and Oreopoulos, D. (2002) Predictors of outcome following bacterial peritonitis in peritoneal dialysis, *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis* 22, 573-581.

17. Oki, R., Tsuji, S., Hamasaki, Y., Komaru, Y., Miyamoto, Y., Matsuura, R., Yamada, D., Doi, K., Kume, H., and Nangaku, M. (2021) Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis, *Sci. Rep.* 11, 6547.
18. Zhao, J., Yang, L., Zhu, X., Zhang, X., Li, X., Liu, S., Zhuang, X., Zhou, W., Luo, P., and Cui, W. (2020) [Clinical characteristics and treatment outcomes of first peritonitis in patients receiving long-term peritoneal dialysis: a multicenter study], Nan fang yi ke da xue xue bao = Journal of Southern Medical University40, 1740-1746.

19. Yang, C., Chen, T., Lin, Y., Lin, C., Ng, Y., Yang, W., and Chen, J. (2008) Determinants of catheter loss following continuous ambulatory peritoneal dialysis peritonitis, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis28, 361-370.

20. Davies, S. J. (2013) Peritoneal dialysis–current status and future challenges, Nature reviews. Nephrology9, 399-408.

21. Lim, W., Boudville, N., McDonald, S., Gorham, G., Johnson, D., and Jose, M. (2011) Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association26, 3366-3372.

22. Krishnan, M., Thodis, E., Ikonomopoulos, D., Vidgen, E., Chu, M., Bargman, J. M., Vas, S. I., and Oreopoulos, D. G. (2002) Predictors of outcome following bacterial peritonitis in peritoneal dialysis, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis22, 573-581.

23. Ma, Y., Wang, Y., Wang, H. Y., Li, Y., Zhou, Z. J., Liu, B. Y., Li, X. M., and Chen, L. M. (2018) Predictors of Short-term Outcomes of Patients with Peritoneal Dialysis-associated Peritonitis, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae40, 13-20.

24. Alharbi, M. A. (2020) Low serum albumin a predictor sign of the incidence of peritoneal dialysis-associated peritonitis? A quasi-systematic review, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia31, 320-334.

25. Ma, T., Chow, K., Kwan, B., Pang, W., Leung, C., Li, P., and Szeto, C. (2016) Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences, Clinical journal of the American Society of Nephrology : CJASN11, 1219-1226.

26. Wu, H., Ye, H., Huang, R., Yi, C., Wu, J., Yu, X., and Yang, X. (2020) Incidence and risk factors of peritoneal dialysis-related peritonitis in elderly patients: A retrospective clinical study, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis40, 26-33.

27. Mehrotra, R., Duong, U., Jiwakanon, S., Kovesdy, C. P., Moran, J., Kopple, J. D., and Kalantar-Zadeh, K. (2011) Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis, American journal of kidney diseases : the official journal of the National Kidney Foundation58, 418-428.

28. Dong, J., Li, Y., Xu, Y., and Xu, R. (2011) Daily protein intake and survival in patients on peritoneal dialysis, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association26, 3715-3721.
29. Htay, H., Seng, J., Yong, M., Pang, S., Wu, S., Chan, C., Sim, M., Johnson, D., and Foo, M. (2019) Comparison of Clinical Presentation and Outcomes of Peritonitis in the Elderly and Younger Peritoneal Dialysis Patients, *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis* 39, 163-168.

30. Zeng, Y., Jiang, L., Lu, Y., Wang, Z., Song, K., Shen, H., and Feng, S. (2021) Peritoneal dialysis-related peritonitis caused by gram-negative organisms: ten-years experience in a single center, *Renal failure* 43, 993-1003.

31. Fung, W., Poon, P., Ng, J., Kwong, V., Pang, W., Kwan, B., Cheng, P., Li, P., and Szeto, C. (2020) Longitudinal Changes of NF-κB Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients, *Sci. Rep.* 10, 6440.

32. Pottanat, N., Brook, A., Bartosova, M., Cortado, H., Gupta, S., Li, B., Jackson, A., Vonau, M., Cohen, S., Ferrara, M., Ching, C., Spencer, J., Brauner, A., Fraser, D., Schmitt, C., Eberl, M., Ayoob, R., and Becknell, B. (2019) Analysis of the Ribonuclease A Superfamily of Antimicrobial Peptides in Patients Undergoing Chronic Peritoneal Dialysis, *Sci. Rep.* 9, 7753.

### Tables

Table 1. Baseline demographic and laboratory parameters of 806 peritoneal dialysis-associated peritonitis episodes in the training dataset.
## Index

**Training dataset (n = 806)**

### Demographic characteristics

| Age (yr)         | 60(48, 69) |
|------------------|------------|
| Gender (male, n, %) | 385(47.8) |
| No. of PDAP episodes | 1(1, 2) |
| PD duration (year)        | 1.34(0.51, 2.62) |
| Antibiotics before admission (yes) | 77(9.6) |

### Protopathy

| Glomerulonephritis | 314(39.0) |
|-------------------|-----------|
| Interstitial nephritis | 37(4.6) |
| Diabetic nephropathy | 197(24.4) |
| Hypertensive renal impairment | 139(39.0) |
| Other             | 119(14.8) |
| Hypertension      | 716(88.8) |
| DM                | 276(34.2) |
| CVD               | 306(38.0) |

### Laboratory test

| WBC ($10^{12}$/L) | 8.38(6.15, 11.35) |
|-------------------|-------------------|
| Hb (g/L)          | 99(84, 112)       |
| Al (g/dL)         | $28.46 \pm 6.34$  |
| BUN (mmol/L)      | 15.62(11.99, 19.82) |
| Scr (μmol/L)      | 711.2(545.00, 895.20) |
| PD cell count on admission (/μL) | 80(60, 130) |

### Organisms (n, %)

| Culture-negative | 132(16.4) |
|------------------|-----------|
| Gram-positive
| Staphylococcus aureus | 34(4.2) |
| Cocoagulase-negative Staphylococcus | 190(23.6) |
| Corynebacterium   | 10(1.2)   |
| Pathogen                                | Count (Percentage) |
|----------------------------------------|--------------------|
| Enterococcus                           | 15 (1.9)           |
| others                                 | 109 (13.5)         |
| **Gram-negative**                      |                    |
| Pseudomonas aeruginosa                 | 11 (1.4)           |
| Escherichia coli                       | 80 (9.9)           |
| Klebsiella Pneumoniae                  | 21 (2.6)           |
| Enterobacter species                   | 18 (2.2)           |
| others                                 | 70 (8.7)           |
| Polymicrobial                          | 75 (9.3)           |
| Fungi or Mycobacterium tuberculosis    | 41 (5.1)           |
| ESI/tunnel infection                   | 30.4               |

DM: Diabetes mellitus; PD: Peritoneal dialysis; WBC: White cell count; Hb: Hemoglobin; Alb: Albumin; BUN: Blood urea nitrogen; Scr: Serum creatinine; PDAP: Peritoneal dialysis-associated peritonitis; CVD: Cardiovascular disease; ESI: Exit-site infection.

Table 2. Univariate and multivariable Logistic regression of cure in the training dataset.
| Variable                                      | Univariate |                  |                  | Multivariable |                  |                  |
|------------------------------------------------|------------|------------------|------------------|---------------|------------------|------------------|
| PD duration (every one year)                   | -0.13      | 0.88 (0.81, 0.95)| 0.00             | -0.14         | 0.87 (0.79, 0.95)| 0.00             |
| Albumin (every 5g/L)                           | 0.18       | 1.20 (1.05, 1.37)| 0.01             | 0.22          | 1.24 (1.06, 1.45)| 0.01             |
| Antibiotics before admission                   | -0.83      | 0.44 (0.27, 0.71)| 0.00             | -0.89         | 0.41 (0.23, 0.74)| 0.00             |
| Type of organisms                              |            |                  |                  |               |                  |                  |
| Culture-negative                               | Reference  |                  |                  |               |                  |                  |
| Gram-positive                                  |            |                  |                  |               |                  |                  |
| Staphylococcus aureus                          | -1.18      | 0.31 (0.13, 0.72)| 0.01             | -1.23         | 0.29 (0.12, 0.70)| 0.01             |
| Cocoagulase-negative Staphylococcus            | -0.03      | 0.97 (0.52, 1.83)| 0.93             | 0.00          | 1.0 (0.53, 1.90) | 1.00             |
| Corynebacterium                                | 0.41       | 1.51 (0.18, 12.64)| 0.70            | 0.32          | 1.38 (0.16, 12.06)| 0.77             |
| Enterococcus                                   | 0.86       | 2.35 (0.29, 18.96)| 0.42            | 0.89          | 2.43 (0.30, 19.83)| 0.41             |
| others                                         | 0.51       | 1.66 (0.74, 3.75)| 0.22             | 0.53          | 1.70 (0.74, 3.92)| 0.21             |
| Gram-negative                                  |            |                  |                  |               |                  |                  |
| pseudomonas aeruginosa                         | -1.97      | 0.14 (0.04, 0.51)| 0.00             | -1.95         | 0.14 (0.04, 0.53)| 0.00             |
| Escherichia coli                               | -0.88      | 0.42 (0.21, 0.83)| 0.01             | -0.82         | 0.44 (0.22, 0.90)| 0.02             |
| Klebsiella Pneumoniae                          | -1.09      | 0.34 (0.12, 0.94)| 0.04             | -1.05         | 0.35 (0.12, 1.01)| 0.05             |
| Enterobacter species                           | -0.83      | 0.44 (0.14, 1.37)| 0.15             | -0.87         | 0.42 (0.13, 1.37)| 0.15             |
| others                                         | -0.40      | 0.67 (0.31, 1.44)| 0.31             | -0.51         | 0.60 (0.27, 1.33)| 0.21             |
| Polymicrobial                                  | -1.03      | 0.36 (0.18, 0.71)| 0.00             | -1.14         | 0.32 (0.16, 0.65)| 0.00             |
| Fungi or Mycobacterium tuberculosis            | -4.75      | 0.01 (0.00, 0.04)| 0.00             | -4.82         | 0.01 (0.00, 0.04)| 0.00             |
Figures

Figure 1
Flowchart of cohort establishment
**Figure 2**

The nomogram for predicting cure of PDAP

**Figure 3**

[Graphs and charts showing statistical analysis results]
a. ROC curve for internal validation of cure

b. Calibration plot for internal validation of cure

Figure 4

a. ROC curve for external validation of cure

b. ROC curve for external validation of cure
Figure 5

The decision curve for cure in the validation dataset.